Vijay Balasubramanian

Valley Medical Center — United States

Medicine · Health Sciences

22h-index1.4kcitations123works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Pulmonary Hypertension Research and Treatments(33), Blood Pressure and Hypertension Studies(15), Cardiac Imaging and Diagnostics(10), Heart Rate Variability and Autonomic Control(10), Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis(8)

Publications121 total

Global Resource Disparities Between Pulmonary Hypertension Centers: Results From the International Survey by the PVRI IDDI Access to Care Workstream
Pulmonary Circulation·2026Open Access
FROM VEINS TO LUNGS: ACUTE PULMONARY EMBOLISM FROM FOAM SCLEROTHERAPY
CHEST Journal·2025Open Access
SOTATERCEPT AND THE VASCULAR-ENDOTHELIAL CONNECTION: A CASE OF THROMBOCYTOPENIA AND TELENGIECTASIA
CHEST Journal·2025Open Access
Honey! I Shrunk the Lungs!
American Journal of Respiratory and Critical Care Medicine·2025
Oral Treprostinil is Associated with Improved Survival in FREEDOM-EV and its Open-Label Extension
Advances in Therapy·2023· 4 citedOpen Access
ORAL TREPROSTINIL IMPROVES SURVIVAL IN FREEDOM-EV AND FREEDOM-EV OPEN-LABEL EXTENSION PARTICIPANTS WITH PULMONARY ARTERIAL HYPERTENSION
CHEST Journal·2023Open Access
Parenteral treprostinil induction for rapid attainment of therapeutic doses of oral treprostinil
Respiratory Medicine·2023· 7 citedOpen Access
Implementing the EXPEDITE parenteral induction protocol: Rapid parenteral treprostinil titration and transition to oral treprostinil
Pulmonary Circulation·2023· 10 citedOpen Access
Remodulin Induction Facilitates Rapid Achievement of Therapeutic Doses of Oral Treprostinil: Results From the EXPEDITE Study
2023· 1 cited
Win Ratio Analysis of the FREEDOM-EV Trial - a Hierarchical Approach to Multiple Clinical Endpoints
2023
Barriers and facilitators to interhospital transfer of acute pulmonary embolism: An inductive qualitative analysis
Frontiers in Medicine·2023· 5 citedOpen Access
Effects of COVID-19 pandemic on the management of pulmonary hypertension
Respiratory Medicine·2022· 5 citedOpen Access
Efficacy and dose-response relationship of oral treprostinil in PAH patients on monotherapy or dual background therapy
European Heart Journal·2022Open Access
Efficacy of oral treprostinil as an add-on therapy for PAH
13.01 - Pulmonary hypertension·2022
Strategies to EXPEDITE the Time to Effective Dosing of Oral Treprostinil in Patients with Pulmonary Arterial Hypertension
2022
Impact of COVID-19 Pandemic on Care of Pulmonary Hypertension Patients
2022· 2 cited
Rapid Titration of Parenteral Treprostinil to EXPEDITE Dosing of Oral Treprostinil
2022
Utilization of risk assessment tools in management of PAH: A PAH provider survey
Pulmonary Circulation·2022· 14 citedOpen Access
Delphi consensus recommendation for optimization of pulmonary hypertension therapy focusing on switching from a phosphodiesterase 5 inhibitor to riociguat
Pulmonary Circulation·2022· 13 citedOpen Access
Hospitalizations in Idiopathic Pulmonary Arterial Hypertension
SSRN Electronic Journal·2022Open Access
page 1 of 7Next →

Frequent Co-authors

Stewart Mann(14), E. B. Raftery(13), Jean Elwing(9), Franck Rahaghi(7), Lana Melendres‐Groves(6), Meredith Broderick(5), E. B. Raftery(4), R. James White(4), Ronald J. Oudiz(4), Orlando P. Simonetti(4), Zeenat Safdar(4), Murali M. Chakinala(4), M.W. Millar‐Craig(4), Avijit Lahiri(3), M. W. Millar Craig(3), B A Gould(3), Robert C. Bourge(3), Oksana A. Shlobin(3), Paaladinesh Thavendiranathan(3), Jennifer A. Dickerson(3)